The course of Disease Activity, infliximab serum concentrations and anti-infliximab antibody concentrations measured, between two standard infliximab infusion time- periods, in patients with rheumatoid arthritis.
Phase 4
- Conditions
- Rheumatoid Arthritis10023213
- Registration Number
- NL-OMON31619
- Lead Sponsor
- Sint Maartenskliniek
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 25
Inclusion Criteria
Patients who had fulfilled the 1987 ACR criteria and had started infliximab therapy for at least 3 months
Exclusion Criteria
There are no exclusioncriteria for this study other than the regulatory contraindications
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>DAS28</p><br>
- Secondary Outcome Measures
Name Time Method <p>infliximab serum levels and anti-inflximab serum levels</p><br>